Clay B. Siegall Buys 66,057 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall acquired 66,057 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The stock was acquired at an average price of $9.54 per share, with a total value of $630,183.78. Following the completion of the transaction, the chief executive officer now directly owns 485,693 shares in the company, valued at $4,633,511.22. This trade represents a 15.74 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Immunome Stock Up 16.8 %

Shares of Immunome stock opened at $13.47 on Thursday. Immunome, Inc. has a 12-month low of $6.93 and a 12-month high of $30.96. The stock has a market cap of $840.80 million, a P/E ratio of -1.65 and a beta of 1.82. The business’s 50 day moving average is $12.41 and its 200-day moving average is $13.52.

Institutional Investors Weigh In On Immunome

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC raised its stake in shares of Immunome by 0.3% during the 3rd quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after purchasing an additional 13,757 shares in the last quarter. Janus Henderson Group PLC raised its stake in Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after acquiring an additional 324,614 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Immunome by 113.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock valued at $55,425,000 after acquiring an additional 1,194,451 shares during the period. Vanguard Group Inc. raised its stake in Immunome by 16.1% in the 1st quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock valued at $49,847,000 after acquiring an additional 279,712 shares during the period. Finally, Marshall Wace LLP raised its stake in Immunome by 228.5% in the 2nd quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock valued at $20,731,000 after acquiring an additional 1,191,774 shares during the period. Institutional investors own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

IMNM has been the topic of several research reports. Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Friday, October 25th. Piper Sandler cut their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, Stephens initiated coverage on Immunome in a research note on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $28.83.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.